Beta-Blockers after Myocardial Infarction in Patients without Heart FailureJohn Munkhaugen, Gro Egholm, Karsten Tange Veien et al.|New England Journal of Medicine|2025Cited by 73
BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point studyJohn Munkhaugen, Dan Atar, Olaf Rødevand et al.|American Heart Journal|2018Cited by 50
A Method for Direct Monitoring of Atorvastatin Adherence in Cardiovascular Disease Prevention: Quantification of the Total Exposure to Parent Drug and Major Metabolites Using 2-Channel Chromatography and Tandem Mass SpectrometryNils Tore Vethe, Stein Bergan, Einar Husebye et al.|Therapeutic Drug Monitoring|2018Cited by 25
Effect of atorvastatin on muscle symptoms in coronary heart disease patients with self-perceived statin muscle side effects: a randomized, double-blinded crossover trialOscar Kristiansen, John Munkhaugen, Stein Bergan et al.|European Heart Journal - Cardiovascular Pharmacotherapy|2020Cited by 25